Literature DB >> 20697362

Organ-sparing approaches for testicular masses.

Alvaro Zuniga1, Nathan Lawrentschuk, Michael A S Jewett.   

Abstract

Organ-sparing approaches are currently practiced in urology for many malignancies. Partial orchiectomy of germ cell tumors (GCT) provides potential benefits over radical surgery by reducing the need for androgen substitution, lessening psychological stress, and preserving fertility, with a durable cure rate. Furthermore, many testicular lesions detected clinically or by ultrasonography will be benign, in which case radical orchiectomy represents overtreatment. Partial orchiectomy for benign lesions allows preservation of endocrine and exocrine function, and reduced risk of local recurrence. However, selection criteria are not clear and one must always be suspicious that a GCT might exist. Carcinoma in situ that remains in the salvaged testicle is a challenge to treat. Radiation therapy is an option, although there is a high chance that patients will subsequently require hormonal replacement. Partial orchiectomy should be undertaken only in selected patients--men with bilateral testicular cancer or GCT in a solitary testis--if the size and location of the mass are amenable to surgery. Informed patient consent discussing radical orchiectomy as the gold standard is mandatory, and discussion of the risks associated with CIS and its treatment, as well as the need for androgen supplementation are paramount. Alternative strategies of organ preservation, such as radiotherapy, HIFU and chemotherapy, might be appropriate treatment options in the future. However, the safety and efficacy of these procedures needs to be demonstrated in comparison with partial orchiectomy in larger and prospective studies with longer follow-up.

Entities:  

Mesh:

Year:  2010        PMID: 20697362     DOI: 10.1038/nrurol.2010.100

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  97 in total

Review 1.  Carcinoma in situ of the testis and bilateral carcinoma.

Authors:  J E Montie
Journal:  Urol Clin North Am       Date:  1993-02       Impact factor: 2.241

2.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

3.  Testis-preserving surgery in bilateral testicular germ cell tumours.

Authors:  A Heidenreich; W Höltl; W Albrecht; J Pont; U H Engelmann
Journal:  Br J Urol       Date:  1997-02

4.  Microsurgical "testis-sparing" surgery for nonpalpable hypoechoic testicular lesions.

Authors:  Luigi Rolle; Andrea Tamagnone; Paolo Destefanis; Andrea Bosio; Massimiliano Timpano; Cristian Fiori; Carlo Ceruti; Paola Burlo; Piera Fauciglietti; Dario Fontana
Journal:  Urology       Date:  2006-08       Impact factor: 2.649

5.  The value of preoperative needle core biopsy for diagnosing benign lesions among small, incidentally detected renal masses.

Authors:  Beverley A Shannon; Ronald J Cohen; Hildemarie de Bruto; Robert J Davies
Journal:  J Urol       Date:  2008-08-15       Impact factor: 7.450

Review 6.  Contralateral testicular biopsy in testis cancer: current concepts and controversies.

Authors:  Axel Heidenreich
Journal:  BJU Int       Date:  2009-11       Impact factor: 5.588

7.  Testicular lesions other than germ cell tumours: feasibility of testis-sparing surgery.

Authors:  Corey Passman; Donald Urban; Katrin Klemm; Mark Lockhart; Phillip Kenney; Peter Kolettis
Journal:  BJU Int       Date:  2008-09-12       Impact factor: 5.588

Review 8.  European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I.

Authors:  Susanne Krege; Jörg Beyer; Rainer Souchon; Peter Albers; Walter Albrecht; Ferran Algaba; Michael Bamberg; István Bodrogi; Carsten Bokemeyer; Eva Cavallin-Ståhl; Johannes Classen; Christoph Clemm; Gabriella Cohn-Cedermark; Stéphane Culine; Gedske Daugaard; Pieter H M De Mulder; Maria De Santis; Maike de Wit; Ronald de Wit; Hans Günter Derigs; Klaus-Peter Dieckmann; Annette Dieing; Jean-Pierre Droz; Martin Fenner; Karim Fizazi; Aude Flechon; Sophie D Fosså; Xavier Garcia del Muro; Thomas Gauler; Lajos Geczi; Arthur Gerl; Jose Ramon Germa-Lluch; Silke Gillessen; Jörg T Hartmann; Michael Hartmann; Axel Heidenreich; Wolfgang Hoeltl; Alan Horwich; Robert Huddart; Michael Jewett; Johnathan Joffe; William G Jones; László Kisbenedek; Olbjørn Klepp; Sabine Kliesch; Kai Uwe Koehrmann; Christian Kollmannsberger; Markus Kuczyk; Pilar Laguna; Oscar Leiva Galvis; Volker Loy; Malcolm D Mason; Graham M Mead; Rolf Mueller; Craig Nichols; Nicola Nicolai; Tim Oliver; Dalibor Ondrus; Gosse O N Oosterhof; Luis Paz Ares; Giorgio Pizzocaro; Jörg Pont; Tobias Pottek; Tom Powles; Oliver Rick; Giovanni Rosti; Roberto Salvioni; Jutta Scheiderbauer; Hans-Ulrich Schmelz; Heinz Schmidberger; Hans-Joachim Schmoll; Mark Schrader; Felix Sedlmayer; Niels E Skakkebaek; Aslam Sohaib; Sergei Tjulandin; Padraig Warde; Stefan Weinknecht; Lothar Weissbach; Christian Wittekind; Eva Winter; Lori Wood; Hans von der Maase
Journal:  Eur Urol       Date:  2007-12-26       Impact factor: 20.096

9.  Multifocality in testicular germ cell tumors.

Authors:  Yaron Ehrlich; Miriam Konichezky; Ofer Yossepowitch; Jack Baniel
Journal:  J Urol       Date:  2009-01-16       Impact factor: 7.450

10.  Imaging of the scrotum: role of MRI.

Authors:  G C Parenti; F Feletti; F Brandini; D Palmarini; S Zago; A Ginevra; P Campioni; P Mannella
Journal:  Radiol Med       Date:  2009-03-30       Impact factor: 3.469

View more
  12 in total

1.  Three primary testicular tumours: Trials and tribulations of testicular preservation.

Authors:  Connor M Forbes; Charles Metcalfe; Nevin Murray; Peter C Black
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

2.  [Carcinoma in situ of the testis].

Authors:  K-P Dieckmann; S Kliesch; M Schrader; S Krege; V Loy
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

Review 3.  [Carcinoma in situ of the testis: predisposition, evolution and early detection].

Authors:  K Biermann
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

4.  Outcomes of organ-sparing surgery for adult testicular tumors: A systematic review of the literature.

Authors:  Jesse Ory; Udi Blankstein; Daniel C Gonzalez; Aditya A Sathe; Joshua T White; Carlos Delgado; John Reynolds; Keith Jarvi; Ranjith Ramasamy
Journal:  BJUI Compass       Date:  2021-02-23

5.  Organ-sparing surgery is the treatment of choice in benign testicular tumors.

Authors:  Nicolai Leonhartsberger; Renate Pichler; Brigitte Stoehr; Wolfgang Horninger; Hannes Steiner
Journal:  World J Urol       Date:  2013-10-04       Impact factor: 4.226

6.  Testis sparing surgery in a case of small unilateral testicular cancer.

Authors:  Hakkı Uzun; Sabri Oğullar; İbrahim Şehitoğlu; Görkem Akça; Orhan Ünal Zorba
Journal:  Turk J Urol       Date:  2013-12

7.  Testis-sparing surgery: Experience in 13 patients with oncological and functional outcomes.

Authors:  Murat Keske; Abdullah Erdem Canda; Ali Fuat Atmaca; Ozer Ural Cakici; Muhammed Ersagun Arslan; Davut Kamaci; Mevlana Derya Balbay
Journal:  Can Urol Assoc J       Date:  2018-08-30       Impact factor: 1.862

Review 8.  Fertility Risk Assessment and Preservation in Male and Female Prepubertal and Adolescent Cancer Patients.

Authors:  Nikolaos Zavras; Charalampos Siristatidis; Argyris Siatelis; Anna Koumarianou
Journal:  Clin Med Insights Oncol       Date:  2016-06-28

9.  Synchronous bilateral testis cancer: clinical and oncological management.

Authors:  Davide Campobasso; Stefania Ferretti; Antonio Frattini
Journal:  Contemp Oncol (Pozn)       Date:  2017-03-22

10.  The survival and prognostic factors of primary testicular lymphoma: two-decade single-center experience.

Authors:  Run-Zhuo Ma; Lei Tian; Li-Yuan Tao; Hui-Ying He; Min Li; Min Lu; Lu-Lin Ma; Hui Jiang; Jian Lu
Journal:  Asian J Androl       Date:  2018 Nov-Dec       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.